EMEA-002468-PIP04-18 - paediatric investigation plan

belantamab mafodotin

Key facts

• Active Substance:
  belantamab mafodotin
• Therapeutic area:
  Oncology
• Decision number:
  P/0347/2019
• PIP number:
  EMEA-002468-PIP04-18
• Pharmaceutical form(s):
  Powder for concentrate for solution for infusion
• Condition(s) / indication(s):
  Treatment of Multiple Myeloma
• Route(s) of administration:
  Intravenous use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  11/09/2020

Decision

P/0347/2019: EMA decision of 11 September 2019 on the granting of a product specific waiver for belantamab mafodotin (EMEA-002468-PIP04-19)

AdoptedReference Number: EMA/439999/2019